Holen Sie sich die Stockscreener-App
1.41
0.70%
-0.01
Schlusskurs vom Vortag:
$1.42
Offen:
$1.41
24-Stunden-Volumen:
105.67K
Relative Volume:
0.03
Marktkapitalisierung:
$146.31M
Einnahmen:
$65,300
Nettoeinkommen (Verlust:
$-84.93M
KGV:
-0.8255
EPS:
-1.708
Netto-Cashflow:
$-83.57M
1W Leistung:
+3.68%
1M Leistung:
+111.08%
6M Leistung:
-18.50%
1J Leistung:
-48.73%
1-Tages-Spanne:
$1.40
$1.42
1-Wochen-Bereich:
$1.325
$1.45
52-Wochen-Spanne:
$0.5632
$2.82
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Firmenname
Inovio Pharmaceuticals Inc
Sektor
Branche
Telefon
(858) 410-3134
Adresse
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.415 | 146.82M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
524.15 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.75 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
997.97 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.54 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
208.35 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-14 | Eingeleitet | Stephens | Overweight |
| 2024-01-25 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-11-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2022-11-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-19 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-12-29 | Fortgesetzt | Jefferies | Hold |
| 2021-09-10 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-24 | Eingeleitet | Jefferies | Hold |
| 2021-03-23 | Eingeleitet | BofA Securities | Neutral |
| 2021-02-12 | Eingeleitet | Oppenheimer | Outperform |
| 2020-11-17 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-11-10 | Hochstufung | ROTH Capital | Sell → Neutral |
| 2020-09-28 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-07-01 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2020-06-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | Herabstufung | Stifel | Buy → Hold |
| 2020-05-21 | Eingeleitet | The Benchmark Company | Buy |
| 2020-04-30 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-03-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-15 | Bestätigt | Maxim Group | Buy |
| 2017-10-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-09-06 | Eingeleitet | Citigroup | Buy |
| 2017-06-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | Bestätigt | Maxim Group | Buy |
| 2017-03-16 | Hochstufung | Maxim Group | Hold → Buy |
| 2017-03-16 | Herabstufung | Piper Jaffray | Overweight → Neutral |
Alle ansehen
Inovio Pharmaceuticals Inc Aktie (INO) Neueste Nachrichten
INOVIO Steps Up Investor Outreach at New York Conferences - MyChesCo
INO Stockholders Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
INOVIO to Participate in Upcoming Investor Conferences - Eastern Progress
Inovio Pharmaceuticals Stock Price Forecast. Should You Buy INO? - StockInvest.us
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio Pharmaceuticals stock gains as analysts see sharp upside - AD HOC NEWS
Investor talks begin Sept. 9 as INOVIO joins two conferences - Stock Titan
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio stock holds in low single digits as losses weigh on outlook - ad-hoc-news.de
Inovio Pharmaceuticals Inc. (INO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio: The Final Countdown To A Binary FDA Decision - Seeking Alpha
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio (INO) Results Versus Estimates: Profit Per Share Clears Its Benchmark in Latest Trading; Market Response: The Stock Ends Down 6.92%Pre-Earnings Setup - Vinanet
Inovio Pharmaceuticals Company Profile & Introduction - Moomoo
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Inovio (INO) Earnings Check: The Available Earnings Metric Delivers a Beat at the Close; Post-Report Move: The Stock Ends Up 4.35% in the Latest ReadingFinancial Data - Vinanet
Q3 EPS Estimate for Inovio Pharmaceuticals Raised by Analyst - MarketBeat
INO Jumps As Inovio Wins Upgrade Ahead Of FDA Decision - timothysykes.com
Inovio Stock Jumps As Jefferies Upgrade Bets On FDA Decision - StocksToTrade
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen - MarketBeat
INOVIO Sets Aug. 12 Earnings Update With Business Review - MyChesCo
Inovio Pharmaceuticals Highlights FDA Inspection Completion and INO-3107 Regulatory Progress in Q2 2026 Earnings CallDividend Earnings Report - Vinanet
HC Wainwright Issues Negative Estimate for INO Earnings - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to Strong-Buy at Zacks Research - MarketBeat
Analysts Have Conflicting Sentiments on These Healthcare Companies: Kura Oncology (KURA) and Inovio Pharmaceuticals (INO) - The Globe and Mail
INO Upgraded by Jefferies -- Price Target Raised to $3.00 - GuruFocus
Piper Sandler Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Jefferies Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Raises Target Price to $3 - Moomoo
H.C. Wainwright reiterates Neutral on Inovio stock, $2.50 target - Investing.com
H.C. Wainwright reiterates Neutral on Inovio stock, $2.50 target By Investing.com - Investing.com Canada
Jefferies upgrades Inovio stock rating on FDA review progress - Investing.com
Inovio Q2 2026 slides: INO-3107 on track for Oct FDA decision - Investing.com Nigeria
Jefferies upgrades Inovio stock rating on FDA review progress By Investing.com - Investing.com Canada
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO): What Does the Latest Update Mean for Regulatory Progress? - Kalkine Media
H.C. Wainwright Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Maintains Target Price $2.5 - Moomoo
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ... - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlig - GuruFocus
Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Inovio Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:INO) 2026-08-12 - Seeking Alpha
Inovio (INO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Inovio Pharmaceuticals, Inc. (INO) stock price, news, quote and history - Yahoo Finance UK
Inovio Q2 EPS $(0.07) beats $(0.22) estimate; loss narrows 74% - scanx.trade
Inovio Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Earnings call transcript: Inovio narrows Q2 2026 loss as INO-3107 nears FDA date - Investing.com
Inovio Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Inovio: Q2 Earnings Snapshot - marketscreener.com
BRIEF-Inovio Pharmaceuticals Q2 Operating Expenses USD 18.6 Million - TradingView
Finanzdaten der Inovio Pharmaceuticals Inc-Aktie (INO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):